{
    "clinical_study": {
        "@rank": "112740", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "ARGX-111 0.3 mg/kg"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "ARGX-111 1.0 mg/kg"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "ARGX-111 3.0 mg/kg"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "ARGX-111 10 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "This a first-in-human study of an antibody blocking the function of the oncogene c-met in\n      patients with cancer."
        }, 
        "brief_title": "A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "This Phase 1b trial will characterize the safety profile of ARGX 111 and will thus provide\n      the first elements towards establishing an accurate risk-benefit assessment for ARGX 111 in\n      cancer patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent.\n\n          2. Age \u2265 18 years.\n\n          3. Performance status of 0 or 1.\n\n          4. Histological diagnosis of malignancy.\n\n          5. Cancer relapsing after, or refractory to standard therapy.\n\n          6. Malignancy over-expressing the c Met protein.\n\n          7. Presence of circulating tumor cells (CTCs).\n\n          8. At least one tumor lesion > 2 cm on PET/CT.\n\n          9. Serum albumin > 35 g/L.\n\n         10. Absolute neutrophil count (ANC) > 1.0 x 109/L.\n\n         11. Hemoglobin > 90 g/L (0.9 g/dL).\n\n         12. Platelet count \u2265 75 x 109/L.\n\n         13. Coagulation parameters \u2264 1.5 x ULN.\n\n         14. Total bilirubin \u2264 1.5 x upper limit of normal (ULN).\n\n         15. Creatine Phosphokinase (CPK) \u2264 2.5 x ULN.\n\n         16. Serum creatinine \u2264 1.5 x ULN.\n\n         17. Ability to comply with protocol-specified procedures/evaluations and scheduled\n             visits.\n\n        Exclusion Criteria:\n\n          1. History or clinical evidence of neoplastic central nervous system (CNS) involvement.\n\n          2. Major surgery within 4 weeks of ARGX 111 first dose administration.\n\n          3. Systemic glucocorticoid administration at doses greater than physiological\n             replacement (prednisone 20 mg equivalent) within 3 weeks of ARGX 111 first dose\n             administration.\n\n          4. Cytotoxic chemotherapy within 3 weeks of ARGX 111 first dose administration.\n\n          5. Radiation therapy with curative intent within 3 weeks of ARGX 111 first dose\n             administration.\n\n          6. Biological therapy (monoclonal antibodies) within 4 weeks of ARGX 111 first dose\n             administration.\n\n          7. Biological therapy (other than monoclonal antibodies) within 5 half-lives of ARGX 111\n             first dose administration.\n\n          8. Unresolved Grade 3 or 4 toxicity from prior therapy, including experimental therapy.\n\n          9. History of recurrent Grade 3 or 4 toxicity from anti c Met therapy.\n\n         10. Uncontrolled diabetes, defined as fasting glycemia > 150 mg/dl).\n\n         11. Active, untreated viral, bacterial, or systemic fungal infection.\n\n         12. Any clinical finding, including psychiatric and behavioral problems, which, in the\n             opinion of the Investigator, precludes the patient from safely participating in the\n             study.\n\n         13. Childbearing potential (unless using an adequate measure of contraception).\n\n         14. Pregnancy or lactation.\n\n         15. History of severe (Grade 3 or 4) hypersensitivity to recombinant proteins."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055066", 
            "org_study_id": "ARGX-111-1301"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm 1", 
                "Arm 2", 
                "Arm 3", 
                "Arm 4"
            ], 
            "intervention_name": "ARGX-111", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer", 
            "c-MET"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "christian.rolfo@uza.be", 
                    "last_name": "Christian Rolfo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium"
                    }, 
                    "name": "Universitair Zieckenhuis Antwerpen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.aftimos@jbi.be", 
                    "last_name": "Philippe Aftimos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "official_title": "A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with grade 3 or 4 toxicity", 
            "measure": "Dose-limiting toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055066"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of drug concentration in the blood", 
                "measure": "Pharmacokinetic profiles (Cmax , Ctrough, AUC, Vd  , clearance, and half-life)", 
                "safety_issue": "Yes", 
                "time_frame": "C1 D1 (pre, 0h, 2h, 6h, 12h, 24h), C1D8, C1D15; Cycle \u22652  o D1 pre-/post-dose"
            }, 
            {
                "description": "measurements of cytokine changes in blood as a result of drug administration", 
                "measure": "Biomarkers (Hepatocyte growth factor; ADCC)", 
                "safety_issue": "Yes", 
                "time_frame": "Base-line and pre-dose at each cycle for an average of 4 months"
            }, 
            {
                "measure": "Incidence of adverse events per dose level", 
                "safety_issue": "Yes", 
                "time_frame": "for an average of 4 months"
            }
        ], 
        "source": "arGEN-X  BVBA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "arGEN-X  BVBA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}